Dassault Systèmes is one of Europe’s largest software companies, and it is having an anxious year. Its shares are down about a quarter this year. It pushed out its chairman in February. And investors worry that a new wave of AI could hollow out its main business.
Its answer, announced on Thursday: spend up to $2 billion on a company most people have never heard of.
The French firm has agreed to buy ArisGlobal, a maker of drug-safety and regulatory software. The price is roughly $1.8 billion in cash, plus up to $200 million more tied to future AI revenue. The seller is Nordic Capital, a Swedish private-equity group that has owned it since 2019. The whole sum comes from Dassault’s own cash pile.
What Dassault is buying
ArisGlobal is not a household name, but it sits deep inside the pharmaceutical industry. Founded in 1989, it is based in Waltham, Massachusetts. It serves more than 200 customers, including half of the world’s 50 biggest drugmakers, plus biotechs and government health regulators. Its software processes more than 12 million patient safety reports a year. It expects revenue of about $175 million in 2026.
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
Its appeal to Dassault is the AI inside it. ArisGlobal’s NavaX system uses generative AI for the grind of drug-safety monitoring and regulatory filing. Those tasks are heavily manual, and heavily policed. The company says it cuts that work by more than 30%. The market for such compliance software could reach $7.5 billion by 2030.
Dassault is not alone in shopping. Legacy software firms, from SAP to Adobe, have bought their way into AI rather than build it from scratch.
The virtual-twin bet
Dassault’s speciality is the “virtual twin,” a detailed digital copy of a real machine, factory or, increasingly, a human body. It uses these to help 390,000 customers design cars, planes and drugs. Chief executive Pascal Daloz wants to fuse that with ArisGlobal’s real-world patient data. The goal, he says, is the industry’s first platform to “unify real-world evidence with virtual evidence.”
“Life Sciences is entering a new era of innovation, driven by AI and the shift to precision medicine,” Daloz said.
ArisGlobal’s chief executive Aman Wasan put it more bluntly. “The future of Life Sciences will not be built on better software. It will be built on connected intelligence.”
A deal born of pressure
The optimism sits on top of real strain. Dassault has spent 2026 among the software firms investors fear AI will upend. The specific threat is “world models,” which let machines grasp the physical world without a hand-built twin. The stock fell hard. The chairman left abruptly in February. This is Dassault’s first big deal since.
Awkwardly, the division it is doubling down on is its weakest. Life-sciences revenue fell 4% in the second quarter and 12% in the first, dragging on results, Bloomberg reported. Its last big health bet, the 2019 purchase of clinical-trials firm Medidata, has underwhelmed. Now it is betting on the same sector again. The wager: that AI turns the laggard into the growth engine.
Investors, for now, approved. Dassault shares rose about 5% on Thursday. It also reported solid quarterly results, with revenue up 4% and cloud growing 14%. The deal should close in the second half of 2026, subject to regulatory approval. Whether it can also quiet the deeper fear, that AI is coming for the twin-makers too, is the harder question.
